Subjects with Borderline Elevated IgE Leveld less Likely to Develop Glioma Subjects with Borderline Elevated IgE Leveld less Likely to Develop Glioma
National Cancer Institute
Subjects with borderline elevated IgE levels less likely to develop glioma
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system’s response to allergies may reduce the risk of developing deadly brain tumors.
People with somewhat elevated blood levels of immunoglobulin E (IgE), antibodies that carry out the body’s immune response to allergens, were significantly less likely to develop gliomas, and those who did survived somewhat longer, than those with clinically normal IgE levels, according to the study by a team of researchers at Brown University and several other institutions in the United States and Europe.
"These results suggest that there is something different about the immune response to tumor cells in people with allergies," said corresponding author Dominique Michaud, associate professor of epidemiology in the Public Health Program at Brown University. "In terms of fighting the cancer or preventing it from growing, people who have allergies might be protected. They might be able to better to fight the cancer."
Questions answered, questions raised
The new study employed a methodology that addresses questions raised by previous studies that have also reported similar associations between IgE, or allergy symptoms, and brain tumors. Instead of asking people who have or have not been diagnosed with brain tumors to describe their allergy history or to take IgE tests, the study delved into the detailed records of tens of thousands of people who participated in four broad-based health studies: the Physicians’ Health Study, the Nurses’ Health Study, the Women’s Health Study, and the Health Professionals Follow-up Study.
Such "prospective" analysis of samples collected from patients before they were diagnosed or treated for brain tumors, allowed the researchers to measure the association between IgE and brain cancer risk without worry that the IgE levels were affected by the course of the disease and treatments for it.